here are the papers.
“Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996517/
This second paper is from 2014 and it has good background on the limitations of Phase 3 trials and good information about ARR vs. RRR.
“The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596394/
These are great. Thank you.